MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2

NCT07076056 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2025-07-21

No results posted yet for this study

Summary

A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy

Conditions

Interventions

DRUG

DW1026C1

Sitagliptin 100mg+Empagliflozin 10mg

DRUG

DW1026C2

Sitagliptin 100mg+Empagliflozin 25mg

DRUG

DW1026S

Sitagliptin 100mg

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-27
Primary Completion
2023-12-04
Completion
2024-06-19

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07076056 on ClinicalTrials.gov